REFERENCES
- Wilson RH, Lehky T, et al. Acute oxaliplatin-induced peripheral nerve hyperxcitability. J Clinic Oncol 2002; 20: 1767–1774.
- Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 1989; 43: 251–60.
- Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
- Becouarn Y, Rougier P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin Oncol 1998; 25: 23–31.
- Giacchetti S, Zidani R, Perpoint B, et al. Phase III multi-center randomized trial of oxaliplatin added to chronomodulat-ed fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136–147.
- de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treat-ment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–2947.
- Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluouracil: Clinical experience in patients with advanced colorectal can-cer. Semin Oncol 1998; 25: 32–39.
- de Gramont A, Vignoud J, Tournigand C et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997; 33: 214–9.
- Misset JL. Oxaliplatin in practice. Br J Cancer 1998 ; 77: 4–7.
- Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990; 322: 126–127.
- Sorbye H, Glimelius B, Berglund A et al. Multicenter phase II study of Nordic fluorouracile and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 1,22 (1): 31-38.
- Norum J. Oxaliplatin in colorectal cancer patients living in an arctic or subarctic area: significant cold-triggered dyses-thesias and laryngeal reactions. J Chemother 2000; 12: 525–529.
- Extra JM, Espie M, Calvo F et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303.
- Brienza S, Vignoud J, Itzhaki M, et al. Oxaliplatin (L-OHP): Global safetyin 682 patients. Proc Am Soc Clin Oncol 14:209, 1995 (abstr 513).
- Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 2003; 30: suppl 15 5-13.
- Taieb S, Trillet-Lenoir V, Rambaud L, et al. Lhermitte sign and urinary retention: Atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002; 94: 2434–2440.
- Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Onc 2002; 29, suppl 15: 11-20.
- Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin based chemotherapy in advanced colorectal cancer: a random-ized, double-blind, placebo controlled trial. J Clin Oncol 2002; 15,20 (16): 3478-3483.
- Levi F, Misset JL, Brienza S et al. A chronopharmaco-logic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorec-tal cancer. Cancer 1992; 69: 893–900.